Thompson Davis & CO. Inc. Acquires New Stake in iCAD, Inc. (NASDAQ:ICAD)

Thompson Davis & CO. Inc. purchased a new stake in shares of iCAD, Inc. (NASDAQ:ICADFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,777 shares of the technology company’s stock, valued at approximately $31,000. Thompson Davis & CO. Inc. owned approximately 0.06% of iCAD as of its most recent SEC filing.

Separately, waypoint wealth counsel grew its stake in shares of iCAD by 44.0% in the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after purchasing an additional 4,400 shares during the last quarter. 24.61% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a research report on Thursday.

Read Our Latest Stock Report on iCAD

iCAD Trading Down 4.6 %

Shares of ICAD opened at $2.70 on Friday. The business’s fifty day simple moving average is $2.46 and its two-hundred day simple moving average is $1.93. iCAD, Inc. has a 12 month low of $1.18 and a 12 month high of $3.78. The company has a market cap of $71.66 million, a price-to-earnings ratio of -20.77 and a beta of 1.47.

iCAD Profile

(Free Report)

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.

Read More

Want to see what other hedge funds are holding ICAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iCAD, Inc. (NASDAQ:ICADFree Report).

Institutional Ownership by Quarter for iCAD (NASDAQ:ICAD)

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.